Skip to main content

Table 1 Demographic characteristics before treatment

From: Dipeptidyl peptidase 4 inhibitor linagliptin can decrease the dosage of erythropoiesis-stimulating agents in patients on hemodialysis

 

DPP4+

DPP4−

P

N

13

16

 

Age

70.5 ± 12.4

71.7 ± 10.2

NS

Male

8

11

NS

BMI

21.7 ± 3.1

22.6 ± 4.1

NS

HD duration

6.5 ± 5.5

10.4 ± 6.2

NS

Hb

10.8 ± 0.6

11.0 ± 0.8

NS

Dosage of DA

23.9 ± 21.2

16.1 ± 12.1

NS

ERI

2.28 ± 2.08

1.52 ± 1.19

NS

Albumin

3.6 ± 0.4

3.5 ± 0.3

NS

TSAT

24.2 ± 6.6

28.9 ± 13.5

NS

Ferritin

264.7 ± 334.6

138.8 ± 137.3

NS

hs-CRP

5335 ± 6494

4345 ± 9372

NS

GA

22.1 ± 5.8

25.2 ± 5.8

NS

  1. DA darbepoetin alfa, ERI erythropoiesis-stimulating agent-resistant index, Hb hemoglobin, TSAT transferrin saturation, BMI body mass index, GA glycated albumin